Hepabig 100 IU Injection is a human hepatitis B immunoglobulin (HBIG) product used to provide immediate, short-term protection against hepatitis B virus (HBV) after specific exposure or in selected high-risk clinical situations. It contains antibodies against hepatitis B surface antigen (HBsAg), helping provide passive immunity while the body develops its own longer-term immune response through vaccination.
For healthcare professionals, hospitals, pharmaceutical distributors, and medical procurement teams looking for information about Hepabig 100 IU Injection uses, understanding its role in hepatitis B prevention is important for appropriate sourcing and clinical use.
What Is Hepabig 100 IU Injection?
Hepabig 100 IU Injection contains human hepatitis B immunoglobulin, which provides ready-made antibodies against HBV. Unlike the hepatitis B vaccine, which stimulates the immune system to develop its own antibodies, HBIG provides passive immunity.
Because passive protection is temporary, HBIG may be administered alongside hepatitis B vaccination when clinically indicated. The exact treatment approach depends on the exposure, vaccination history, HBsAg status of the source, and the patient's clinical circumstances.
Hepabig 100 IU Injection Uses
One of the main Hepabig 100 IU Injection uses is post-exposure prophylaxis against hepatitis B. It may be considered when a person has been exposed to blood or body fluids that could contain HBV.
Potential clinical situations include:
- Accidental occupational exposure among healthcare workers
- Exposure to blood or potentially infectious body fluids
- Certain household or close-contact exposures
- Prevention of HBV infection in newborns at risk following maternal HBV infection
- Other situations where immediate passive immunization is clinically indicated
HBIG is generally most effective when administered as soon as possible following an eligible exposure. Healthcare professionals determine whether HBIG is required based on established hepatitis B post-exposure protocols.
Hepabig 100 IU Injection for Newborns
Prevention of mother-to-child transmission is an important application of hepatitis B immunoglobulin. Infants born to mothers who are positive for hepatitis B surface antigen may require specific preventive measures shortly after birth.
Depending on applicable clinical guidelines and the mother's HBV status, HBIG together with hepatitis B vaccination may be recommended for an at-risk newborn. Timely administration is important because early prevention can significantly reduce the risk of perinatal HBV transmission.
The baby's healthcare team determines the appropriate product, dose, timing, and follow-up based on the clinical situation.
How Does Hepabig Work?
Hepabig provides anti-HBs antibodies directly to the recipient. These antibodies can help neutralize hepatitis B virus and reduce the likelihood of infection after exposure.
The protection provided by HBIG is temporary. Vaccination works differently by stimulating the individual's immune system to create its own protective antibodies. Therefore, in certain situations, HBIG and hepatitis B vaccine are used as complementary preventive measures rather than alternatives.
Hepabig 100 IU Injection Administration
Hepabig should be administered by a qualified healthcare professional according to the approved product information and applicable medical guidelines. The dose, route, timing, and need for repeat administration depend on the indication and patient-specific factors.
It should not be self-administered or used without appropriate medical assessment. Healthcare providers should also verify the product's storage conditions, expiry date, packaging integrity, and batch information before administration.
Possible Side Effects
As with other immunoglobulin products, some individuals may experience temporary reactions. These can include:
- Pain, redness, or swelling at the injection site
- Fever
- Headache
- Fatigue
- Nausea
- Mild allergic-type reactions
Serious hypersensitivity reactions are uncommon but can occur. Medical professionals should monitor patients appropriately and manage significant reactions according to established clinical procedures.
Hepabig 100 IU Injection Storage and Handling
Proper storage is essential for maintaining the quality of human immunoglobulin products. Hepabig should be stored and handled according to the manufacturer's approved product information and packaging instructions. Healthcare facilities and pharmaceutical distributors should maintain appropriate temperature control throughout storage and transportation.
For pharmaceutical procurement, buyers should verify product availability, pack details, batch information, expiry, documentation, and shipping requirements before placing an order.
Sourcing Hepabig 100 IU Injection from India
Global Pharma Trade, based in Nagpur, India, can support pharmaceutical sourcing requirements for products such as Hepabig 100 IU Injection, subject to product availability and applicable export and import regulations.
Hospitals, pharmaceutical distributors, healthcare procurement organizations, and authorized buyers seeking Hepabig 100 IU Injection from India can enquire regarding product specifications, commercial quotations, packaging, documentation, and international supply requirements.
Frequently Asked Questions
What is Hepabig 100 IU Injection used for?
Hepabig 100 IU Injection is a hepatitis B immunoglobulin product used to provide temporary passive protection against HBV in specific post-exposure and other high-risk situations.
Is Hepabig the same as the hepatitis B vaccine?
No. Hepabig provides ready-made antibodies for temporary protection, while the hepatitis B vaccine stimulates the body to develop its own immune response.
Can Hepabig be used after hepatitis B exposure?
HBIG may be recommended following certain exposures to HBV. A healthcare professional should assess the exposure and determine whether HBIG and vaccination are appropriate.
Who should administer Hepabig?
Hepabig should be administered by an appropriately qualified healthcare professional following the approved prescribing information and applicable clinical guidelines.
Conclusion: Hepabig 100 IU Injection has an important role in selected hepatitis B prevention strategies, particularly where immediate passive immunity is required after potential HBV exposure. Appropriate medical assessment, timely administration, vaccination when indicated, and proper product handling are essential components of effective hepatitis B prevention.
